Ipamorelin vs Cjc 1295
Which Is Right for You? Complete Comparison (2026)
Selective GHRP vs GHRH analogue — often stacked together but serve different roles.
Ipamorelin vs Cjc 1295: At a Glance
- ✓Selective growth hormone releasing peptide (GHRP)
- ✓Stimulates pituitary GH release via ghrelin/GHS-R1a receptor
- ✓Does not significantly elevate cortisol, prolactin, or aldosterone
- ✓Produces a clean GH pulse similar to natural secretion
- ✓Half-life approximately 2 hours — administered 2-3x daily
- ✓Modified GHRH(1-29) analogue — stimulates GH release at the pituitary
- ✓DAC version binds albumin, extending half-life to ~8 days
- ✓Non-DAC (Mod GRF 1-29) has half-life of ~30 minutes
- ✓Produces sustained GH and IGF-1 elevation
- ✓Often stacked with GHRPs (e.g., Ipamorelin) for synergistic effect
Detailed Comparison
| Feature | Ipamorelin | Cjc 1295 |
|---|---|---|
| Mechanism | Growth hormone secretagogue (selective GHRP) | Growth hormone releasing hormone analogueBest |
| Dosing | 200-300 mcg SC 2-3x daily | DAC: 2 mg/week SC; No-DAC: 100 mcg 2-3x daily |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Half-life | ~2 hours | DAC: ~8 days; No-DAC: ~30 min |
| FDA Status | Not FDA-approved — research peptide | Not FDA-approved — research peptide |
| Key Trial | Raun K et al. Eur J Endocrinol 1998 — demonstrated selective GH release | Teichman SL et al. JCEM 2006 — sustained GH/IGF-1 elevation |
| Side Effects | Headache, flushing, dizziness, injection site irritation — generally well-tolerated | Flushing, headache, injection site reactions, water retention |
Which Should You Choose?
Ipamorelin (growth hormone secretagogue (selective ghrp)) and CJC-1295 (with or without DAC) (growth hormone releasing hormone analogue) serve different clinical roles despite both being in the GH secretagogue space. Ipamorelin selective gh secretagogue that stimulates gh release from the pituitary via ghrelin receptor without significantly raising cortisol, prolactin, or aldosterone. CJC-1295 (with or without DAC) modified ghrh(1-29) analogue that stimulates pituitary gh secretion with extended half-life via drug affinity complex (dac) binding to albumin.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Ipamorelin vs Cjc 1295: Frequently Asked Questions
Ipamorelin is a growth hormone secretagogue (selective ghrp) while CJC-1295 (with or without DAC) is a growth hormone releasing hormone analogue. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
Ipamorelin works as a growth hormone secretagogue (selective ghrp) (200-300 mcg SC 2-3x daily), while CJC-1295 (with or without DAC) is a growth hormone releasing hormone analogue (DAC: 2 mg/week SC; No-DAC: 100 mcg 2-3x daily). They have different half-lives (~2 hours vs DAC: ~8 days; No-DAC: ~30 min), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Track Ipamorelin or Cjc 1295 in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.